Sangamo BioSciences and Collaborators to Present Data on ZFP Therapeutic Applications and Developments at Annual Meeting of the American Society of Gene and Cell Therapy

RICHMOND, Calif., May 14, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics® will be presented at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Fourteen oral and poster presentations, given by Sangamo scientists and their academic collaborators, will detail data from Sangamo's therapeutic and research programs including HIV/AIDS, Huntington's disease and other monogenic diseases, cancer immunotherapy and advancements in the technology including delivery. The meeting will be held in Washington, DC, from May 21-24, 2014.

"We are pleased that the diversity and maturity of Sangamo's ZFP Therapeutic platform will be highlighted at this important gene therapy research forum," said Edward Lanphier, Sangamo's president and CEO. "Data from these clinical and preclinical studies demonstrate the versatility, efficiency and precision of Sangamo's technology as applied to a range of therapeutic applications."

The following presentations are scheduled at the ASGCT Meeting sessions:

HIV/AIDS

- HIV Protected Autologous Zinc Finger Nuclease Driven CCR5 Modified CD4 T-Cells
- Cross-Clade Inhibition of HIV on Primary Cells by CXCR4 or CCR5 Fused to the

CANCER


MONOGENIC DISEASES

- Allele-Specific Repression of Mutant Huntingtin Expression By Engineered Zinc Finger Transcriptional Repressors as a Potential Therapy for Huntington's Disease [Abstract #603]; Session: "Neurological Diseases II," Friday, May 23, 2014.

TECHNOLOGY DEVELOPMENT AND OTHER APPLICATIONS


All abstracts for the ASGCT meeting are available online at 2014 ASGCT Annual Meeting
About Sangamo

Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures™ for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS (SB-728-T) and NGF-AAV for Alzheimer’s disease (CERE-110). Sangamo’s other therapeutic programs are focused on monogenic and rare diseases. The company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington’s disease and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company’s website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

Logo - https://photos.prnewswire.com/prnh/20130102/SF35903LOGO

SOURCE Sangamo BioSciences, Inc.